DrugPatentWatch Database Preview
Drugs in Development Information for Ipatasertib
Development status for investigational drug Ipatasertib: Patents, clinical trial progress, indications
Ipatasertib is an investigational drug.
There have been 19 clinical trials for Ipatasertib.
The most recent clinical trial was a Phase 1 trial, which was initiated on June 20th 2017.
The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and Medical Research Council.
There are twenty-four US patents protecting this investigational drug and three hundred and seventy-eight international patents.
Summary for Ipatasertib
| US Patents | 24 |
| International Patents | 378 |
| US Patent Applications | 49 |
| WIPO Patent Applications | 28 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2017-06-20) |
| Vendors | 45 |
Recent Clinical Trials for Ipatasertib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer | Hoffmann-La Roche | Phase 3 |
| AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) | Genentech, Inc. | Phase 1 |
| AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) | Massachusetts General Hospital | Phase 1 |
Clinical Trial Summary for Ipatasertib
Top disease conditions for Ipatasertib
Top clinical trial sponsors for Ipatasertib
US Patents for Ipatasertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ipatasertib | See Pricing | Polymeric nanoparticles and methods of making and using same | Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY) | See Pricing |
| Ipatasertib | See Pricing | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use | GENENTECH, INC. (South San Francisco, CA) | See Pricing |
| Ipatasertib | See Pricing | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | Array BioPharma Inc. (Boulder, CO) Covenentech, Inc. (South San Francisco, CA) | See Pricing |
| Ipatasertib | See Pricing | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | Array Biopharma, Inc. (Boulder, CO) Genentech, Inc. (South San Francisco, CA) | See Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ipatasertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ipatasertib | European Patent Office | 3119395 | 2034-03-17 | See Pricing |
| Ipatasertib | World Intellectual Property Organization (WIPO) | 2015142605 | 2034-03-17 | See Pricing |
| Ipatasertib | Australia | 2012236135 | 2031-04-01 | See Pricing |
| Ipatasertib | Australia | 2012236138 | 2031-04-01 | See Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
